

ASX RELEASE
Ellex Medical Lasers Limited (ASX:ELX)
Adelaide, Australia



Date: 28 March 2019

Release: Immediate

Topic: Ellex iTrack[®] featured at the 8th World Glaucoma Congress in Melbourne

Adelaide, Australia, 28 March 2019 – Ellex Medical Lasers Limited (ASX:ELX; OTCQX: ELXMY, ELXMF), a world leader in medical technologies for the diagnosis and treatment of eye disease, today announced an Ellex sponsored clinical symposium on Ellex iTrack[®] to be hosted at the 8th World Glaucoma Congress (WGC) in Melbourne, Australia on 28 March 2019.

The symposium will educate clinicians on the use and benefits of ABiC[™] (*ab interno* canaloplasty) performed with the iTrack surgical system in patients with intermediate to late stage glaucoma. The keynote address will be given by Dr. Mahmoud A. Khaimi, Clinical Associate Professor at the Dean McGee Eye Institute, University of Oklahoma. The pioneer of the ABiC procedure, Dr. Khaimi has treated more than 4,000 patients with the iTrack ABiC procedure. The symposium will also feature Dr. David Lubeck, Chief Medical Officer (CMO) of Ellex, Dr. Deric de Wit, Barossa Eye Clinic, Adelaide, and Dr. Inder Paul Singh, The Eye Centers of Racine and Kenosha, Wisconsin.

Approximately 300,000 Australians have glaucoma, of which 50% remain undiagnosed¹. According to Medicare data², the use of stent-based minimally invasive glaucoma surgery (MIGS) procedures in Australia increased by more than 700% during 2014-2017. Ellex iTrack is a highly effective, restorative MIGS procedure that flushes out the natural outflow channels without damaging tissue, and without leaving behind a stent or shunt.

During the WGC, Ellex CMO Dr. Lubeck will present a small case study³ assessing the effectiveness of iTrack in lowering intraocular pressure (IOP), reducing topical medication dependence and reducing symptomatic ocular surface disease in patients who had previously undergone stent-based MIGS with iStent[™] (Glaukos (NYSE:GKOS)). The results across 4 patients (7 eyes) demonstrated iTrack could be used effectively to reduce IOP, as well as the need for topical medications in ocular surface disease in previously treated patients, without disturbing the in-place stent. Patients were monitored postoperatively for up to two years.

Mr. Tom Spurling, CEO of Ellex, commented: “As clinical experience grows, we expect to see further studies and publications in support of iTrack as a primary MIGS option for patients. It is worth noting, however, that iTrack also has an important role to play further down the glaucoma treatment paradigm, following and/or in conjunction with other MIGS procedures. Dr

¹ <https://www.glaucoma.org.au/>

² Newman, D and Andrew, N. 2018. Changes in Australian practice patterns for glaucoma management. Clin Exp Ophthalmol 13.

³ Lubeck, D. The use of ABiC (ab-interno canaloplasty) to lower intraocular pressure and reduce topical medication related symptomatic ocular surface disease in patients having undergone microtrabecular bypass surgery. [World Glaucoma Congress (WGC) 2019. Poster presentation.]

Lubeck has demonstrated that in patients with glaucoma, where the disease has progressed following iStent implantation, iTrack is highly effective. Importantly, iTrack, unlike iStent, can be used in patients that have already had cataract surgery. This offers surgeons a highly effective stent-free MIGS option that can be deployed following failed stent-based MIGS procedures in order to eliminate or defer the need for invasive, late-stage glaucoma surgery.”

- ENDS -

ABOUT ELLEX

Ellex designs, develops, manufactures and sells innovative product that help eye surgeons around the world to effectively and efficiently treat eye disease. Ellex is a world leader in this field. Headquartered in Adelaide, Australia, Ellex has ophthalmic lasers and devices that treat glaucoma, retinal disease primarily caused by diabetes, secondary cataract and vitreous opacities, as well as age-related macular degeneration. Manufacturing is carried out in Adelaide, Australia and Fremont, California. Sales and service directly to eye surgeons is conducted via subsidiary offices in Minneapolis, Lyon, Berlin and Tokyo. A network of more than 50 distribution partners around the world services other markets.

For additional information about Ellex and its products, please visit www.ellex.com

For further information on Ellex please contact:

Tom Spurling
CEO
Ellex Medical Lasers Limited
3 Second Avenue, Mawson Lakes SA 5095
W +61 8 7074 8293 | M +61 417 818 658
tspurling@ellex.com

Dr. Tom Duthy
Investor Relations & Corporate Development
Ellex Medical Lasers Limited
3 Second Avenue, Mawson Lakes SA 5095
M +61 402 493 727
tduthy@ellex.com

Maria Maieli
CFO & Company Secretary
Ellex Medical Lasers Limited
3 Second Avenue, Mawson Lakes SA 5095
W +61 8 7074 8200
mmaieli@ellex.com

Julia Maguire
Media Relations
The Capital Network
M: +61 419 815 386
julia@thecapitalnetwork.com.au

